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Abstract
The combination of Marfan syndrome with lymphoma is extremely rare. This report describes a case of Marfan syndrome 
who presented with chest discomfort and was diagnosed to have an aortic aneurysm and an additional incidental medi-
astinal mass that on further investigation turned out to be a diffuse large B cell lymphoma. We have suggested a hypoth-
esis which can explain the occurrence of lymphoma in Marfan syndrome. (Turk J Hematol 2009; 26: 31-3)
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Özet
Marfan sendromu ile lenfoma kombinasyonu oldukça enderdir. Bu rapor, göğüs rahatsızlığı ile gelen ve aort anevrizması ve 
tesadüfen ilave bir mediastinal kitlesi olduğu tespit edilen bir Marfan sendromu olgusunu anlatmaktadır. Daha ileri bir tetkik 
ile bu mediastinal kitlenin diffüz büyük B hücreli lenfoma olduğu açığa çıkmıştır. Marfan sendromunda lenfoma oluşumunu 
açıklayabilen bir hipotez ileri sürdük. (Turk J Hematol 2009; 26: 31-3)
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Introduction
The combination of Marfan syndrome with lymphoma 
is extremely rare. Marfan syndrome can present with dif-
ferent complications, of which aortic dissection and valvu-
lar aortic regurgitation are perhaps the most dreaded. 
Case Report
A 66-year-old man presented with light-headedness 
and discomfort in his throat and chest and minimal 
weight loss. The findings on physical examination were 
consistent with Marfan syndrome: height of 184 cm and 
the lower segment was disproportionately longer, with a 
high-arched palate, mild dolichocephaly and positive 
thumb sign. He did not have any evidence of anemia, 
hepatosplenomegaly or clinically significant lymphade-
nopathy.
On echocardiography, he was found to have an 
aortic regurgitation with possible aortic aneurysm. On 
further imaging (T2-weighted magnetic resonance imag-ing [MRI]-fast spoiled gradient-echo [FSPGR]), it was found 
that he had an aneurysm of the ascending aorta (7.3x7.2 cm) 
and additionally a mass in the anterior mediastinum (9.6x5.2 cm). 
A computerized tomography (CT)-guided biopsy of the mass 
revealed a diffuse large B-cell lymphoma. The lymphoid cells 
examined showed CD 20, BCL 2 and BCL 6 positivity. The 
tumor had a high proliferation rate and almost all cells were 
Ki67 positive.
He underwent chemotherapy (rituximab CHOP) and on 
follow-up scan the lymphoid mass had almost disappeared 
(10x6 mm) and no longer had high metabolic activity as estab-
lished by positron emission tomography (PET) scan.
The aneurysm remained stable and is being followed. 
Currently, the patient is on no medications and is doing well.
Discussion
Marfan syndrome is a disorder of connective tissue and is 
associated with ectopia lentis, flat cornea, increased axial 
length of globe, hypoplastic iris or hypoplastic ciliary muscles, 
and various skeletal abnormalities. Cardiovascular abnormali-
ties include aortic dissection and aortic regurgitation. Those 
with Marfan syndrome have a greater chance of spontaneous 
pneumothorax, striae atrophicae, recurrent or incisional hernia, 
and lumbosacral dural ectasia. The diagnosis is based on the 
revised diagnostic criteria for Marfan syndrome [1].
The clinical presentation may be chest discomfort because 
of an aortic aneurysm. Though in this case it was difficult to 
ascertain the exact cause of the chest discomfort, it could well 
have been due to either the aortic aneurysm with aortic regur-
gitation or the mediastinal mass (lymphoma). The diagnosis of 
the aortic dissection was made initially by echocardiography 
and confirmed by MRI.
Diffuse large B-cell lymphoma is treated with combination 
chemotherapy. In this case, the patient had complete remis-
sion with combination chemotherapy.
The combination of Marfan syndrome with lymphoma is 
extremely rare. The first report of the said association was 
published in Italian [2]. The second case was recently reported 
from Greece [3]. Our patient, it would appear, is the third to be 
reported in the world literature.
What could possibly be the connection between Marfan syn-
drome and lymphoma? Is there any common underlying mecha-
nism that can unify the two? The answer is not yet known. 
We know that Marfan syndrome is an autosomal dominant 
disorder and is caused by an abnormality in the fibrillin-1 gene 
located on chromosome 15. Fibrillin-1 is normally present in 
the matrix and regulates activation of transforming growth fac-
tor (TGF)-β. Dysregulation of TGF-β activation is said to con-
tribute to the pathogenesis of Marfan syndrome. Aberrant 
activation of TGF-β by dysfunctional fibrillin-1 has also been 
thought to be the central abnormality in the pathogenesis of 
aortic aneurysm and myxomatous valve changes in Marfan 
syndrome [4]. Studies have also linked mutation in genes 
encoding TGF-β receptor 2 with familial aortic aneurysm and 
dissection [5]. Similar mutations have been reported in Marfan 
syndrome [6].
TGF-βs are multifunctional growth factors that have a criti-
cal role in cell proliferation, cell cycle arrest, differentiation, 
programmed cell death, and matrix deposition. It is an impor-
tant negative regulator of normal lymphocytes and can induce 
apoptosis. TGF-βs are synthesized as pre-propolypeptides 
and then processed in Golgi apparatus to produce mature 
TGF-β and its propeptide (latency associated peptide [LAP]). 
Dimers of mature TGF-β and LAP form a complex - small 
latency complex (SLC) - which is covalently bound to another 
protein called latent TGF-β binding protein (LTBP), forming a 
large latent complex (LLC) that is secreted into the extracellular 
space where it binds to the extracellular matrix. Fibrillin-1 nor-
mally present in the extracellular matrix binds LLC and acts to 
limit the activation of TGF-β [7]. It seems that alteration in 
fibrillin-1 in Marfan syndrome diminishes the ability of fibrillin-1 
to sequester the LLCs and this releases excess TGF-β into the 
matrix, leading to abnormal matrix.
Smad proteins play a key role in signal transduction of family 
members of TGF-β. Through Smad-1, TGF-β affects prolifera-
tion, survival and differentiation of cells (including malignant 
lymphocytes). Aberrant Smad pathway signalling has a 
pathophysiological role in non-Hodgkin’s lymphomas (Figure 1).
TGF-β binds to cell surface receptors (TGFBRII). The com-
plex so formed recruits and phosphorylates TGFBRI receptor 
to form a Type I/Type II receptor complex. The activated Type I 
receptor provides anchorage for receptor Smad protein 
(R-Smad) and induces phosphorylation of R-Smads and asso-
ciated Smad-1 and Smad-4 (serine-threonine change in 
C-terminal end). The phosphorylated Smad translocates to the 
nucleus and regulates gene expression and causes increased 
proliferation of the malignant cells.
TGFBRII blocking antibodies inhibit Smad-1 phosphoryla-
tion and Smad-1/Smad-4 complex formation, and inhibits 
events further downstream.
In high-grade lymphomas, TGF-β expression is twice that 
seen in low-grade non-Hodgkin’s lymphoma. As mentioned 
above, phosphorylation of Smad-1 is normally mediated by 
TGF-β in the microenvironment [8].
Studies have confirmed the role of the TGF-β high-produc-
er genotype as a risk factor of non-Hodgkin’s lymphoma. In 
addition, it has been shown that such patients have clinically 
and histologically more aggressive disease. The TGF-β gene 
polymorphism, in addition, has been shown to influence the 
course of disease in non-Hodgkin’s lymphoma patients. Those 
with certain mutations (TCGG or TTGG) tend to present with 
two or more extranodal site involvements [9]. Thus, it would 
seem that TGF-β plays a key role in the pathogenesis and 
course of disease in non-Hodgkin’s lymphoma patients.
It has been reported recently that there is probably a role of 
fibrillin-1 and TGF-β in the pathogenesis and course of hepa-
tocellular carcinoma in patients with coexistent aortic dissec-
tion [10]. 
Further research is needed for a better understanding of a 
possible unifying pathogenesis.
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Figure 1. In Marfan syndrome, there is abnormal fibrillin; therefore, there is 
impaired binding of large latent complex to fibrillin. Thus, more active TGF-
beta is released by proteases